NASDAQ:RNAZ TransCode Therapeutics Q3 2025 Earnings Results & Report $1.68 +0.05 (+3.07%) Closing price 04:00 PM EasternExtended Trading$1.76 +0.08 (+4.46%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. TransCode Therapeutics beat analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$5.49 versus the -$9.24 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 14, 2025TimeBefore Market OpensConference Call4:00 PM ET TransCode Therapeutics EPS ResultsActual EPS-$5.49Consensus EPS -$9.24Beat/MissBeat by +$3.75One Year Ago EPSN/ATransCode Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTransCode Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) TransCode Therapeutics Q3 2025 Earnings FAQ Did TransCode Therapeutics beat earnings estimates for Q3 2025? TransCode Therapeutics (NASDAQ:RNAZ) reported earnings of -$5.49 per share for Q3 2025, beating the consensus estimate of -$9.24. The report was announced on Friday, November 14, 2025. When is TransCode Therapeutics' next earnings date? TransCode Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for TransCode Therapeutics on the company's earnings history page. TransCode Therapeutics Earnings HeadlinesTransCode Therapeutics (NASDAQ:RNAZ) Stock Jumps 12.1% - Still a Buy?October 6, 2026 | americanbankingnews.comTransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-UpSeptember 28, 2026 | prnewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 13 at 1:00 AM | Porter & Company (Ad)TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-OncologySeptember 22, 2026 | prnewswire.comTransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer TranscriptSeptember 16, 2026 | seekingalpha.comJoin Today’s Live Investor Webinar with TransCode TherapeuticsSeptember 16, 2026 | usatoday.comSee More TransCode Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TransCode Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransCode Therapeutics and other key companies, straight to your email. Email Address About TransCode TherapeuticsTransCode Therapeutics (NASDAQ:RNAZ), Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for the treatment of cancer, particularly metastatic disease. The company’s approach is designed to use targeted therapeutic agents to interfere with biological processes that enable cancer cells to spread. Its lead product candidate, TTX-MC138, is an investigational therapy designed to target microRNA-10b, a molecule associated with the development and progression of metastatic tumors. TransCode is evaluating the candidate as a potential treatment for multiple solid-tumor cancers and is advancing its broader RNA therapeutic platform for oncology applications. TransCode is headquartered in Boston, Massachusetts, and conducts its development activities primarily in the United States. As a development-stage biotechnology company, its products remain investigational and require further clinical testing and regulatory review before they may become commercially available.View TransCode Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
